Johnson & Johnson $JNJ Stock: Sanders Morris Harris LLC Grows Stake

Sanders Morris Harris LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 185.8% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 8,197 shares of the company’s stock after purchasing an additional 5,329 shares during the period. Sanders Morris Harris LLC’s holdings in Johnson & Johnson were worth $2,197,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in the stock. Fairfield Financial Advisors LTD increased its position in Johnson & Johnson by 23.2% in the 3rd quarter. Fairfield Financial Advisors LTD now owns 1,924 shares of the company’s stock valued at $509,000 after acquiring an additional 362 shares in the last quarter. Consilium Wealth Advisory LLC increased its holdings in shares of Johnson & Johnson by 8.9% in the third quarter. Consilium Wealth Advisory LLC now owns 9,575 shares of the company’s stock worth $2,535,000 after acquiring an additional 782 shares in the last quarter. Investment Planning Advisors Inc. lifted its stake in Johnson & Johnson by 13.3% in the third quarter. Investment Planning Advisors Inc. now owns 2,155 shares of the company’s stock valued at $570,000 after buying an additional 253 shares in the last quarter. ABLE Financial Group LLC boosted its holdings in shares of Johnson & Johnson by 8.1% in the third quarter. ABLE Financial Group LLC now owns 2,381 shares of the company’s stock valued at $630,000 after buying an additional 179 shares during the period. Finally, First Citizens Bank & Trust Co. raised its holdings in shares of Johnson & Johnson by 71.8% during the third quarter. First Citizens Bank & Trust Co. now owns 52,947 shares of the company’s stock worth $14,017,000 after acquiring an additional 22,136 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Elizabeth Forminard sold 15,918 shares of the firm’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the sale, the executive vice president directly owned 16,994 shares in the company, valued at $4,367,458. This trade represents a 48.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of the firm’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at $5,779,963.81. This represents a 50.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 87,569 shares of company stock worth $23,064,544. 0.16% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on JNJ. Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Royal Bank Of Canada cut their price objective on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a report on Wednesday. Stifel Nicolaus set a $260.00 price target on shares of Johnson & Johnson in a research note on Wednesday, July 15th. Johnson Rice reiterated a “buy” rating on shares of Johnson & Johnson in a report on Monday, August 3rd. Finally, Scotiabank reiterated an “outperform” rating and set a $305.00 target price on shares of Johnson & Johnson in a research note on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $273.61.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ exceeded third-quarter adjusted earnings expectations, reporting EPS of $2.59 versus a $2.53 consensus, while revenue rose 5.9% year over year to $25.4 billion. Innovative Medicine was the primary growth engine, with reported 7.9% growth and strong demand for newer products. Johnson & Johnson reports Q3 2026 results and raises 2026 guidance
• Positive Sentiment: The company raised its 2026 outlook to $101.0 billion-$101.4 billion in revenue and $11.05-$11.15 in adjusted EPS. The improved forecast provides support for the stock despite the quarter’s mixed details. JNJ Q3 earnings call highlights
• Positive Sentiment: JNJ declared a quarterly dividend of $1.34 per share, equivalent to $5.36 annually and approximately a 2.2% yield, reinforcing its appeal to income-focused investors. Johnson & Johnson announces quarterly dividend

Johnson & Johnson Stock Up 2.0%

Shares of NYSE JNJ opened at $253.49 on Thursday. The stock has a 50-day moving average price of $265.80 and a two-hundred day moving average price of $249.47. The company has a market cap of $610.89 billion, a price-to-earnings ratio of 38.41, a PEG ratio of 2.54 and a beta of 0.21. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12 month low of $184.66 and a 12 month high of $281.07.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The firm had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same period last year, the firm posted $2.80 earnings per share. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts forecast that Johnson & Johnson will post 11.10 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s payout ratio is 62.11%.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.